Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Accured Expenses (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Change in Accured Expenses readings, the most recent being $76.5 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 1.03% to $76.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $160.2 million, a 269.12% increase, with the full-year FY2025 number at $160.2 million, up 269.12% from a year prior.
  • Change in Accured Expenses hit $76.5 million in Q4 2025 for Neurocrine Biosciences, up from $55.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $124.4 million in Q3 2023 to a low of -$98.3 million in Q4 2023.
  • Median Change in Accured Expenses over the past 5 years was $17.1 million (2021), compared with a mean of $21.2 million.
  • Biggest five-year swings in Change in Accured Expenses: soared 1691.67% in 2021 and later crashed 467.28% in 2024.
  • Neurocrine Biosciences' Change in Accured Expenses stood at $19.1 million in 2021, then surged by 96.86% to $37.6 million in 2022, then crashed by 361.44% to -$98.3 million in 2023, then soared by 178.64% to $77.3 million in 2024, then fell by 1.03% to $76.5 million in 2025.
  • The last three reported values for Change in Accured Expenses were $76.5 million (Q4 2025), $55.8 million (Q3 2025), and $15.5 million (Q2 2025) per Business Quant data.